Steglatro

Chemical Nameertugliflozin
Dosage FormTablet (oral; 5 mg, 15 mg)
Drug ClassInhibitors
SystemEndocrine
CompanyMerck & Co.
Approval Year2017

Indication

  • To improve glycemic control in adults with type 2 diabetes mellitus.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Steglatro (ertugliflozin) Prescribing Information 2020Merck Sharp & Dohme Corp.